R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Moffitt Cancer Center

J. Chavez

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

CAR T-Cell vs. Bispecific Therapies for Blood Cancers: How Oncologis…

GRACE

A. Goodman, A. Jeong, S. Rajeeve

Endocrine Adverse Events From Checkpoint Inhibitors

Yale Cancer Center

K. Herold

Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

Sequencing of Bispecifics With Other Therapies in DLBCL

UChicago Medicine

E. Budde

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…

Tara Graff

Will Immune Therapy Replace Transplant in Hematologic Malignancies?

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

R. Gale

R/R DLBCL Case Discussion: 81 y/o Male Needing 3rd Line Treatment

Total Health

J. Chandler, B. Randolph, M. Onciu

ASCO® 2023 Insights: "Primary OS Analysis of the Phase 3 Randomized …

Insights from 2023 ASCO® Annual Meeting

J. Westin

Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Goi…

University of Colorado Department of Medicine

J. Gutman

Current Management of DLBCL From Frontline to Relapsed Disease

Dipenkumar Modi

Treatment Updates and Management of Non-Hodgkin Lymphomas

Integrity CE

D. Wallace, M. Cortese

CAR T-Cell Therapy in Autoimmune Disorders

Vanderbilt University Medical Center (VUMC)

O. Oluwole

Understanding CRISPR and Gene Editing in the Treatment of Heme Malig…

UChicago Medicine

A. Cooper

R/R DLBCL: Are CAR-Ts Superior to Bispecific Antibodies?

Moffitt Cancer Center

A. Lazaryan

Considering Alternatives to CAR-T in R/R DLBCL

Julio Chavez

Risk of Second Malignancies and T-Cell Lymphoma After CAR T-Cell The…

Stanford Medicine

M. Hamilton

ASH 2023 Insights: "Outpatient Management of CAR-T and Bi-Specific A…

Insights from 2023 ASH Annual Meeting

R. Bansal